Form 4: Castle Biosciences COO Sells Shares Under 10b5-1 Plan

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported a sale of common stock executed under a pre-arranged trading plan.

Summary

• Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc., reported a transaction involving the sale of common stock.
• The sale occurred on June 16, 2026, and was executed under a Rule 10b5-1 trading plan adopted on March 17, 2026.
• A total of 8,587 shares were sold at a weighted-average price of $20.71 per share, with individual transaction prices ranging from $20.51 to $20.95.
• Following this transaction, Oelschlager directly beneficially owns 30,460 shares of common stock.
• Additionally, 97,251 shares are held indirectly through The Fritz Shorter Trust, where Oelschlager and her spouse serve as trustees and beneficiaries.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the sale of shares by a key executive, despite being executed under a pre-planned 10b5-1 strategy. The sale reduces direct insider holdings.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related activity.
• The reporting person maintains significant indirect beneficial ownership through The Fritz Shorter Trust.

Negatives

• A notable number of shares were sold by a key executive.
• The sale represents a reduction in direct beneficial ownership by the COO.

Risks

• Potential for negative market perception due to a significant sale by a high-ranking executive, even if conducted under a 10b5-1 plan.
• The weighted-average sale price of $20.71 could be viewed in the context of the stock's recent trading performance and future expectations.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Management Comments

• The transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.
• The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances. However, the volume and timing relative to company performance can influence investor sentiment.

Related Party Transactions

• The sale of common stock by Kristen M. Oelschlager, Chief Operating Officer.
• Indirect beneficial ownership of 97,251 shares by The Fritz Shorter Trust, where the reporting person and her spouse are trustees and beneficiaries.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though mitigated by the Rule 10b5-1 plan. The sale reduces direct insider ownership.
• Employees: The sale by a senior executive might influence employee sentiment regarding the company's stock.
• Management: Demonstrates adherence to pre-established trading plans for personal financial management.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan.
• The company may provide further updates on executive shareholdings in subsequent filings.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Beneficial Ownership, Common Stock, Kristen M. Oelschlager